


ECAT Information: Fibrin(ogen) Degradation Products Pilot Study

In Spring 2023 a small pilot study was performed on testing for Fibrin(ogen) Degradation Products (FDP). The meaning of this pilot study was to investigate the feasibility of an external quality assessment survey for FDP. In total 14 laboratories took part in this pilot study, 9 of which have returned results.

The table below shows a summary of the results reported.

Sample	All (µg/mL)			Stago Liatest FDP			Werfen HemosIL FDP		
	Median	Range	CV (%)	Median	Range	CV (%)	Median	Range	CV (%)
	n = 11			n = 2			n = 9		
22.FDP1	5.7	4.2 – 6.9	16.5	6.4	6.0 – 6.9	9.8	5.1	4.2 – 6.8	16.8
22.FDP2	3.2	2.5 – 4.9	18.3	4.3	3.8 – 4.9	17.3	3.2	2.5 – 3.7	12.3
22.FDP3	9.1	7.8 – 12.3	16.0	9.7	9.2 – 10.2	7.5	8.4	7.8 – 12.3	17.7

The figure below shows the individual results per method for the different samples used.



This pilot study has demonstrated that it is feasible to organise surveys for Fibrin(ogen) Degradation Products. Because of the limited number of results returned, the outcome of this pilot study should be interpreted with caution.

It seems that on average lower values are measured with the Werfen method in comparison to the Stago method. This is most likely caused by the lack of standardisation for this parameter.

In 2024 the ECAT Foundation will begin regular surveys for Fibrin(ogen) Degradation Products.